Ciencia Latina Revista Científica Multidisciplinar · Sep 11, 2026

Osteosarcopenia: an update on diagnosis and treatment. An emerging geriatric syndrome or the arithmetic sum of two conditions?

By Amaya RIR, Herrera SCG, Gonzalez NMR et al.

OBJECTIVE: To critically synthesize the evidence on the definition, diagnosis, prognostic value, and treatment of osteosarcopenia, and to determine whether the coexistence of low bone mass and sarcopenia provides incremental utility over its individual components. DESIGN: Critical narrative review (Grant & Booth taxonomy), with an explicit search strategy and predefined selection criteria. It is not a systematic review in accordance with PRISMA 2020: no meta-analysis, formal risk-of-bias assessment, or duplicate screening was performed. SOURCES: PubMed/MEDLINE from inception through August 2026, supplemented by semantic searching, prioritizing consensus documents, systematic reviews with meta-analyses, randomized trials, and prospective cohorts. MAIN SYNTHESIS: The pooled prevalence in postmenopausal women is 15.6 % (IC 95 %: 9.6–24.3), with extreme heterogeneity (I² = 97.1 %) attributable to the absence of a unified operational definition. In cross-sectional designs, osteosarcopenia is more strongly associated with fragility fracture than either of its components (OR 3.70; IC 95 %: 1.94–7.04). The meta-analysis of prospective studies with formal interaction analysis found neither additive synergy (RERI 0.35; IC 95 %: −0.22 to 0.91) nor multiplicative synergy (MR 1.21; IC 95 %: 0.90–1.62) for incident fracture, and the risk was comparable to that of low bone mineral density alone (RR 1.22; IC 95 %: 0.96–1.56). In advanced chronic kidney disease and hemodialysis, the construct did outperform its components, with grip strength as the dominant predictor. Progressive resistance training with nutritional support is the only intervention with randomized evidence for both compartments; the benefit is rapidly reversed after detraining. There is no approved drug for the muscle component. CONCLUSIONS: Based on current evidence, osteosarcopenia constitutes a robust prognostic marker and a trigger for multidomain intervention, but not a nosologically independent diagnosis. Its operational value lies in correcting two systematic omissions in primary care: muscle is not assessed in patients with osteoporosis, nor is bone assessed in patients with sarcopenia.

doi.org/10.37811/cl_rcm.v10i4.25607Open accessBiomarkers

AgingResearch.News